Authorized purpose: TruSPECT Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals; TruClear AI SPECT enhancement supports the existing image-processing workflow and does not replace clinical judgment.
Clinical role
PET image enhancement, reconstruction, or quantitative image-processing support before professional review.
Images and patients
PET/SPECT/Nuclear Medicine · Heart, organs, and body regions represented in SPECT studies
Key limitation
Keep in mind: The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, quantitative use, and fallback workflow determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: TruSPECT Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals; TruClear AI SPECT enhancement supports the existing image-processing workflow and does not replace clinical judgment.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Heart, organs, and body regions represented in SPECT studies Input: Supported PET list-mode, sinogram, or reconstructed data with required CT and acquisition metadata.
Who uses it?Intended users: Qualified nuclear-medicine physicians, radiologists, technologists, and trained PET/CT professionals.
What does the software produce?Output: Processed PET image series, quantitative values, and visual identifiers for professional review.
What is its most important limitation?Key limitation: The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, quantitative use, and fallback workflow determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
Clinical takeaway. Clinical role: TruSPECT Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals; TruClear AI SPECT enhancement supports the existing image-processing workflow and does not replace clinical judgment.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and integration testing and a multi-center retrospective validation of AI denoising using 352 patients from three hospitals, with a held-out test set of 24 patients (74 images). Against clinical routine high-count SPECT references, it reported LVEF r=0.94, EDV r=0.98 and TPD r=0.98, Bland–Altman mean differences within pre-specified criteria, and visual similarity ratings of 'similar'. Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
TruSPECT Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals; TruClear AI SPECT enhancement supports the existing image-processing workflow and does not replace clinical judgment.
The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, quantitative use, and fallback workflow determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
The exact FDA document reports software verification and integration testing and a multi-center retrospective validation of AI denoising using 352 patients from three hospitals, with a held-out test set of 24 patients (74 images). Against clinical routine high-count SPECT references, it reported LVEF r=0.94, EDV r=0.98 and TPD r=0.98, Bland–Altman mean differences within pre-specified criteria, and visual similarity ratings of 'similar'. Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Evaluation activities included software verification, system integration and performance testing, simulated-use testing, and risk-based assessments." … "Validation was performed using a multi-center, retrospective dataset of 352 patients (137 female, 215 male; mean age 65.4±12.4 years; BMI 29.4±6.4) from three hospitals in the UK and Germany.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and integration testing and a multi-center retrospective validation of AI denoising using 352 patients from three hospitals, with a held-out test set of 24 patients (74 images). Against clinical routine high-count SPECT references, it reported LVEF r=0.94, EDV r=0.98 and TPD r=0.98, Bland–Altman mean differences within pre-specified criteria, and visual similarity ratings of 'similar'. Clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Evaluation activities included software verification, system integration and performance testing, simulated-use testing, and risk-based assessments." … "Validation was performed using a multi-center, retrospective dataset of 352 patients (137 female, 215 male; mean age 65.4±12.4 years; BMI 29.4±6.4) from three hospitals in the UK and Germany.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K253532 FDA evidence package for TruSPECT Processing Station
DesignFDA software substantial-equivalence decision with SPECT processing, AI enhancement, phantom, clinical-image, and usability verification
PopulationSPECT and nuclear-medicine image-processing workflows for cardiology, electrophysiology, organ-function, and other labeled uses
Scopeexact submission
Tested versionTruSPECT Processing Station configuration described in K253532
IndependenceSponsor or vendor study
K253532
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K253532 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported PET list-mode, sinogram, or reconstructed data with required CT and acquisition metadata.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes a processing workstation intended for acceptance, transfer, display, storage, and processing of images, which can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station; testing confirmed compliance with NEMA PS3.1–3.20. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "TruSPECT is intended for acceptance, transfer, display, storage, and processing of images for detection of radioisotope tracer uptakes" … "The workstation can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Processed PET image series, quantitative values, and visual identifiers for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Processed PET image series, quantitative values, and visual identifiers for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes a processing workstation intended for acceptance, transfer, display, storage, and processing of images, which can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station; testing confirmed compliance with NEMA PS3.1–3.20. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "TruSPECT is intended for acceptance, transfer, display, storage, and processing of images for detection of radioisotope tracer uptakes" … "The workstation can be integrated with the D-SPECT cardiac scanner system or used as a standalone post-processing station.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Only qualified nuclear-medicine physicians, radiologists, technologists, and trained pet/ct professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, and downtime contract locally.
product family · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, quantitative use, and fallback workflow determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The cleared tracer, reconstruction input, scanner, acquisition, dose, noise level, quantitative use, and fallback workflow determine applicability; image-processing benefit is not a universal diagnostic-performance claim.
product family · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: uMI Panvivo variants acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, attenuation correction, and the labeled body-region workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Authorized purpose: uMI Panvivo PET/CT acquires anatomical CT and functional PET images of radiopharmaceutical distribution for qualified diagnostic and treatment-planning workflows, including labeled lung-cancer-screening use.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, head and neck, cardiac, and other labeled PET/CT regions
Authorized purpose: Cartesion Prime PET/CT acquires cross-sectional CT images and PET radiopharmaceutical-distribution images and includes AiCE-i PET processing and a neural-network respiratory-gating workflow for supported examinations.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, head, neck, cardiac, and other labeled PET/CT regions
Authorized purpose: uMI Panvivo and Panvivo S acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, and the labeled oncology, cardiology, neurology, infection, inflammation, radiotherapy-planning, and interventional workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.